Engineering and Manufacturing
Adeno-Associated Viral (AAV) Vectors
Methods Editor:
Hildegard Büning, PhD
Hannover Medical School
Adeno-associated viral (AAV) vectors have not only emerged as one of the most widely used delivery tools in conventional gene therapy, but have also gained comparable popularity in gene editing. However, efficiencies and safety of gene transfer or transgene expression can be remarkably improved by tailoring the AAV capsid and/or the vector genome. Likewise, production yield, vector purification processes as well as QC have profited from implementing state-of-the art engineering and monitoring technologies.
Based on these improvements, Human Gene Therapy Methods is assembling a special issue to provide an in-depth insight into the current state-of-the art of AAV vector engineering and to report on the most recent developments to improve vector manufacturing.
Protocols as well as original and review articles are sought in the following general categories:
- Capsid engineering strategies (both rational and library based)
- Novel capsid variants and their characterization
- Optimizing AAV vector genomes for efficient, inducible, and/or long-term transgene expression
- Influencing vector (genome) fate
- Next-generation packaging cell lines or production protocols
- Quality control (quantification of impurities)
Visit the Human Gene Therapy Methods website to learn about the benefits of submitting and for manuscript submission instructions.
Click here to submit your paper online directly to our web-based manuscript submission and peer-review system.